ClinicalTrials.gg
RecruitingNCT04115254Updated Nov 13, 2025

Stereotactic Magnetic Resonance Guided Radiation Therapy

An interventional study of MR-guided Linac in Pancreas Cancer, Lung Cancer and Renal Cancer, sponsored by Dana-Farber Cancer Institute. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-13.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2019; still recruiting 7 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
397
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute — 5 open to participants now, 7 under way, none of them phase 3. Pancreatic Neoplasms · Dana-Farber Cancer Institute.

Planned enrollment
4th of 23
397 · median 36
Started
2019
with 2 others
No phase
9 of 25
3 open now
Registered
19th of 25
by date

Among the 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute, this one is the 4th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 with no phase, and was the 19th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

5 of the 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Pancreatic Neoplasms by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.

  • The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer.
  • Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures
Read the detailed description

This research study is a feasibility study, which means it is the first-time investigators at this institution are examining this type of MR-guided radiation to treat cancer.

The U.S. Food and Drug Administration (FDA) has approved this device as a treatment option for cancer.

In this research study, the investigators are hoping to determine if adjusting radiation treatments based on daily MRI has a feasible way to deliver radiation for participants with pancreatic, lung or renal cancer.

03

Conditions studied

  • Pancreas Cancer
  • Lung Cancer
  • Renal Cancer
  • Adrenal Metastases
  • Prostate Cancer
  • Liver Metastases
  • Oligoprogressive Nodal Metastases
  • Metachronous Nodal Metastases
  • Synchronous Nodal Metastases
  • Mesothelioma
  • Spine Metastases
  • Brain Metastases
  • Borderline Resectable Pancreatic Carcinoma

Keywords

  • Magnetic Resonance Imaging (MRI)
  • MRIdian Linear Accelerator
  • Pancreas Cancer
  • Lung Cancer
  • Renal Cancer
  • Adrenal Metastases
  • Prostate Cancer
  • Liver Metastases
  • Oligoprogressive
  • Metachronous
  • Synchronous
  • Spine
  • Prostate Boost
  • Pelvic Re Irradiation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a confirmed requiring stereotactic body radiation therapy. See specific disease site cohorts for more details.
  • Tumor size ≤ 7cm
  • Age 18 years of older.
  • performance status ≤2 ( ≥60%, see Appendix A)
  • Ability to understand and the willingness to sign a written document.
  • Specific eligibility requirements for each disease site with be covered in each specific cohort.

Exclusion criteria

Exclusion Criteria:

  • Specific exclusion requirements for each disease site with be covered in each specific cohort
  • History of allergic reactions attributed to gadolinium-based IV contrast.

    -- Note: If a patient will not receive contrast, this is not applicable

  • Pregnant women are excluded from this study.
  • Severe claustrophobia or anxiety
  • Participants who cannot undergo an MRI
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
397 participants (estimated)

Study arms

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Pancreatic

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Renal

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Central Lung

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Adrenal Metastases

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Liver Metastases

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Metachronous Oligometastatic Nodes

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Oligoprogressive Oligometastatic Nodes/Soft Tissue

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Synchronous Oligometastatic Nodes/Soft Tissue

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Prostate

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Borderline Resectable Pancreas

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Brain Metastases

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Mesothelioma

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Prostate Boost

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Pelvic Re-Irradiation

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Spine

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Single-Fraction Kidney Tumors

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--1/3 Fraction for Oligometastatases in the Abdomen/Pelvis

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Post-Operative Radiation Therapy in Lung Cancer

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

  • Experimental
    PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Mediastinal and Hilar Lymph Nodes

    SMART will be administered per each individual disease site standards

    Radiation: MR-guided Linac

Interventions

  • RadiationMR-guided Linac

    Radiation will be delivered on an MR-guided Linear Accelerator

06

What researchers measure

Primary outcomes

  1. Delivery Success Rate for SMART across multiple tumors-Phase I

    Enrolling patients and delivering SMART on the MR Linac

    Time frame: 1 year

  2. Tumor visualization-Phase I

    Assessing tumor using MR guidance before, during and after MR-guided treatment patient

    Time frame: 1 Year

  3. Plan creation-Phase I

    Generating adaptive plans

    Time frame: 1 Year

  4. Rate of Improvement in Tumor Control-Phase II

    Statistical power will be defined in each cohort individually and will be specific to each disease site tested.

    Time frame: 1 Year

Secondary outcomes

  1. Number of Patients with Acute Toxicity-Phase I

    Any related ≥ Grade 3 AE which is possibly, probably or definitely related to SMART

    Time frame: 90 Days

  2. Duration of treatment-Phase 1

    Duration of treatment with goal of \>80% of cases treated within 90 minutes

    Time frame: 90 Days

  3. Number of treatment fractions-Phase1

    Number of treatment fractions that would have resulted in unacceptably high dose (exceeding constraint) to an OAR without SMART

    Time frame: 90 Days

  4. Number of Participants with long term toxicity-Phase II

    assessing long-term (12 month) toxicity in patients receiving SMART

    Time frame: 365 Days

  5. Disease Specific Survival Rate-Phase II

    Kaplan-Meier curve estimates

    Time frame: 365 Days

  6. Overall Survival Rate-Phase II

    Kaplan-Meier curve estimates

    Time frame: 365

07

Study locations

2 of 2 sites recruiting
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Jonathan Leeman, MD · Contact
    • Jonathan Leeman, MD · Principal investigator
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
    Recruiting
    • Jonathan Leeman, MD · Contact
    • Jonathan Leeman, MD · Principal investigator
08

References and documents

Publications

  • Leeman JE, Shin KY, Droznin A, Catalano P, Cagney DN, Singer L, Oniyangi RD, Zhai K, Benham G, Chirmade S, Campbell J, Boyle S, Saranteas A, Williams CL, Huynh E, Han Z, Sudhyadhom A, Hu YH, Ferguson D, Singhrao K, Hsu SH, Bredfeldt J, Martin NE, Mancias JD, Mamon HJ, Van Dams R, Venkatachalam V, Tanguturi SK, Huynh MA, Fitzgerald KJ, Elhalawani H, Bitterman DS, Schoenfeld JD, Nguyen P, Haas-Kogan DA, Mak R. Stereotactic magnetic resonance imaging-guided adaptive radiotherapy: a pooled analysis of a master prospective trial. J Natl Cancer Inst. 2025 Nov 1;117(11):2289-2297. doi: 10.1093/jnci/djaf208. PubMed 40794880 ↗

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Dr. Jonathan Leeman (jonathane_leeman@dfci.harvard.edu). The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: BWH - Contact the Partners Innovations team at http://www.partners.org/innovation

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Jun 2028, 104 months after the start.

Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 104 months is above that.

Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2019
First posted
Oct 3, 2019
StartActual
Oct 22, 2019
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04115254
Responsible party
Jonathan Leeman, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Oct 3, 2019
Start date
Oct 22, 2019
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 13, 2025

Study contacts

Jonathan Leeman, MD
Contact
JONATHANE_LEEMAN@DFCI.HARVARD.EDU
617-732-6452
Jonathan Leeman, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion